Monika Ádori

Monika Ádori

Auto-generated profile, based on publicly available information

Monika Ádori

Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2026 in Nature
Verified
Journal Article
Open access
PDF file
JGJavier Guenaga
Javier Guenaga
MÁMonika Ádori
Monika Ádori
SBShridhar Bale
Shridhar Bale
SPSwastik Phulera
Swastik Phulera
IZIoannis Zygouras
Ioannis Zygouras
RWRichard T Wyatt
Richard T Wyatt
As a chronically replicating virus, HIV has evolved extreme sequence variability and effective shielding of functionally constrained spike protein determinants by host-derived glycans 1 . Broadly neutralizing antibodies, although rare, can be isolated from people living with HIV, revealing conserved envelope glycoprotein (Env) sites as key targets for vaccine development 2–4 . One such target is the apex of the Env spike. Here we identify a vaccination strategy using heterologous HIV Env trimers covalently coupled to liposomes for multivalent display that resulted in the elicitation of cross-neutralizing HIV serum antibody responses in all trimer-liposome-immunized non-human primates. Critically, we isolated monoclonal antibodies from multiple macaques that cross-neutralize divergent HIV clinical isolates. High-resolution cryogenic electron microscopy structural analyses of monoclonal antibodies from four different macaques demonstrate that they target the Env trimer apex in a manner highly similar to that of the human-infection-elicited, apex-directed broadly neutralizing antibody PG9, representing a substantial advance in HIV vaccine development.